Drug Profile

JMKX 000623

Alternative Names: JMKX-000623; ODM-111

Latest Information Update: 14 Nov 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Jemincare
Developer Jemincare; Orion
Class Non-opioid analgesics; Small molecules
Mechanism of Action Nav1.8 voltage-gated sodium channel inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Discontinued Neuropathic pain; Pain

Most Recent Events

24 Oct 2024 Discontinued - Phase-I for Pain (In volunteers) in Netherlands based on the risk-benefit analysis on the results of a longer non-clinical toxicology study (PO)
24 Oct 2024 Discontinued - Phase-II for Neuropathic pain in China based on the risk-benefit analysis on the results of a longer non-clinical toxicology study (PO)
08 Aug 2024 Orion plans a phase II trial for Pain during 2024 or early 2025

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com